cerrar
Tagged with GE

Japan: The Latest Therapeutic Applications in Induced Pluripotent…
Toshio Fujimoto, MBA, MD of Japan’s Shonan Health Innovation Park looks at how a technology developed in Japan over a decade ago is poised to drive…

The German Biotech Behind Pfizer’s COVID-19 Vaccine Candidate
German biotech BioNTech has been thrust into the global spotlight thanks to its collaboration with global giant Pfizer on a COVID-19 vaccine. The…

Axel B Müller – Managing Director, Intergenerika,…
Intergenerika’s Dr Axel B. Müller makes an impassioned case against the introduction of a reference pricing system in Switzerland, arguing that it…

Katharina Gasser – Managing Director, Biogen Switzerland…
Biogen Switzerland’s Dr Katharina Gasser outlines how the company’s 100 percent commitment to neuroscience helps it to stand apart, why…

Paying for Cell & Gene Therapy in the USA: Is the Future…
Certara’s Ulrich Neumann looks at the challenges that payment models for cell and gene therapy (CGT) have faced, the multiple models now under…

China: The Pharma Deals Keep Coming
The latest from Chinese pharma, with dealmaking continuing apace. Featured this week are Zai Lab’s latest IPO listing in Hong Kong, InventisBio…

Market Access in Switzerland: Reimbursement Delays for 76% of New…
Switzerland, rightly regarded as one of the world’s most innovative nations, risks damaging its reputation if innovative new medicines continue to…

Jan Børge Jakobsen – MD, Bayer Norway
Jan Børge Jakobsen, managing director of Bayer Norway, shares how he came to lead Bayer’s Norwegian affiliate after 30 years within the Norwegian…

Biosimilar Adoption in the US: Still Lagging Behind Europe
As part of our upcoming US Healthcare and Life Sciences Review, we spoke to key stakeholders – former Association for Accessible Medicines (AAM)…

Jon Amund Kyte – Head, Department of Experimental Cancer…
[caption id="attachment_92156" align="alignleft" width="227"] Photo: Sofia Linden / Oslo Cancer Cluster[/caption] Oncologist Jon Amund Kyte shares…

Chinese Biotech Strategies: Biologics or Small Molecules
While the vast majority of the global pharma market still comprises small molecule drugs, the biologics sector has grown rapidly since its inception…

Pharma’s Data Problem
Drs David Higgins and Marco F Schmidt highlight the gap that exists between the abundant discussions around technological innovation in healthcare and…
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here